Skip to content

Characterization of HIV-1 Antibody Resistance in Patients

Characterization of HIV-1 Antibody Resistance in Patients - HIVAR

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00027018
Enrollment
210
Registered
2022-01-10
Start date
2023-02-02
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B24

Interventions

Group 1: - Blood draws

Sponsors

Universitätsklinikum Köln
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 18 years or older - Karnofsky-Index =80% - HIV Infection

Exclusion criteria

Exclusion criteria: Only for blood draws >100ml: - Hemoglobin <13.5 g/dL (men) or <12.5 g/dL (women) - Symptomatic heart disease (e.g., heart failure NYHA =II, coronary artery disease, previous myocardial infarction). - Has had a myocardial infarction. - Stage GOLD III-IV COPD. - Body weight less than 45kg (To perform a blood draw of =250 mL there must be a body weight of at least 50 kg) - <8 weeks (men) or <12 weeks (women) since last blood volume draw of =500 mL - Known acquired or hereditary coagulation disorder, including therapeutic Anticoagulation - Within one week of a minor surgery (e.g., biopsy, tooth extraction, etc.), or one month after major surgery (e.g., opening of the chest cavity or abdomen) or other surgery with increased risk of postoperative bleeding (e.g., removal of the palatine tonsils [tonsillectomy]). - Current participation in an interventional study. Current participation is defined as when the patient is in the treatment or follow-up phase of a clinical trial, or when another interventional procedure has been performed or is planned for another type of study in temporal relation to the leukapheresis or blood collection. In the latter case, it is crucial that an overlap of study-related harms or a disproportionate burden for the patient is excluded from a medical point of view.

Design outcomes

Primary

MeasureTime frame
Recruiting 350 patients

Secondary

MeasureTime frame
Does not apply.

Countries

Germany

Contacts

Public ContactPhilipp Schommers

Uniklinik Köln

philipp.schommers@uk-koeln.de+49 221 478 89659

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026